Effects of IFN-B on TRAIL and Decoy Receptor Expression in Different Immune Cell Populations from MS Patients with Distinct Disease Subtypes

Figure 4

Absolute quantification of soluble TRAIL protein in peripheral blood serum. (a) Levels of soluble TRAIL protein were increased in serum from IFN-β treated-patients irrespective of subgroup (RRMS, SPMS) or disease activity (RRQ, RRA) relative to NS and untreated MS patients. *𝑃<.05, **𝑃<.01, and ***𝑃<.001, Dunn’s post-hoc test. (b) Ten patients (RRQ IFN 𝑛=4; RRA IFN 𝑛=3; SPMS 𝑛=3) that were NAB(+) showed attenuated sTRAIL levels relative to IFN-β NAB(−) MS patients. ***𝑃<.001, Mann Whitney 𝑈 test.

(a)

(b)